creatine-supplementation-neurodegeneration

Migration, Crosslink

📖

creatine-supplementation-neurodegeneration

active

wiki page Created: 2026-04-02T07:18:58 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-creatine-supplementati

📖 Wiki Page

therapeutic3971 wordssynced 2026-04-02

Creatine Supplementation for Neurodegenerative Diseases

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">creatine-supplementation-neurodegeneration</th>
</tr>
<tr>
<td class="label">Dimension</td>
<td>Score (0–10)</td>
</tr>
<tr>
<td class="label">Mechanistic Clarity</td>
<td>8</td>
</tr>
<tr>
<td class="label">Clinical Evidence</td>
<td>3</td>
</tr>
<tr>
<td class="label">Preclinical Evidence</td>
<td>7</td>
</tr>
<tr>
<td class="label">Replication</td>
<td>5</td>
</tr>
<tr>
<td class="label">Effect Size</td>
<td>3</td>
</tr>
<tr>
<td class="label">Safety/Tolerability</td>
<td>9</td>
</tr>
<tr>
<td class="label">Biological Plausibility</td>
<td>8</td>
</tr>
<tr>
<td class="label">Actionability</td>
<td>7</td>
</tr>
<tr>
<td class="label">Total</td>
<td>50/80</td>
</tr>
<tr>
<td class="label">Phase</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Loading (optional)</td>
<td>20 g/day in 4 divided doses</td>
</tr>
<tr>
<td class="label">Maintenance</td>
<td>3–5 g/day</td>
</tr>
<tr>
<td class="label">PSP/CBS recommended</td>
<td>5 g/day (no loading)</td>
</tr>
<tr>
<td class="label">Form</td>
<td>Bioavailability</td>
</tr>
<tr>
<td class="label">Creatine monohydrate</td>
<td>>90%</td>
</tr>
<tr>
<td class="label">Creatine ethyl ester</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Buffered creatine (Kre-Alkalyn

...

Creatine Supplementation for Neurodegenerative Diseases

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">creatine-supplementation-neurodegeneration</th>
</tr>
<tr>
<td class="label">Dimension</td>
<td>Score (0–10)</td>
</tr>
<tr>
<td class="label">Mechanistic Clarity</td>
<td>8</td>
</tr>
<tr>
<td class="label">Clinical Evidence</td>
<td>3</td>
</tr>
<tr>
<td class="label">Preclinical Evidence</td>
<td>7</td>
</tr>
<tr>
<td class="label">Replication</td>
<td>5</td>
</tr>
<tr>
<td class="label">Effect Size</td>
<td>3</td>
</tr>
<tr>
<td class="label">Safety/Tolerability</td>
<td>9</td>
</tr>
<tr>
<td class="label">Biological Plausibility</td>
<td>8</td>
</tr>
<tr>
<td class="label">Actionability</td>
<td>7</td>
</tr>
<tr>
<td class="label">Total</td>
<td>50/80</td>
</tr>
<tr>
<td class="label">Phase</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Loading (optional)</td>
<td>20 g/day in 4 divided doses</td>
</tr>
<tr>
<td class="label">Maintenance</td>
<td>3–5 g/day</td>
</tr>
<tr>
<td class="label">PSP/CBS recommended</td>
<td>5 g/day (no loading)</td>
</tr>
<tr>
<td class="label">Form</td>
<td>Bioavailability</td>
</tr>
<tr>
<td class="label">Creatine monohydrate</td>
<td>>90%</td>
</tr>
<tr>
<td class="label">Creatine ethyl ester</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Buffered creatine (Kre-Alkalyn)</td>
<td>Similar to monohydrate</td>
</tr>
<tr>
<td class="label">Creatine hydrochloride</td>
<td>Similar</td>
</tr>
<tr>
<td class="label">Creatine magnesium chelate</td>
<td>Unknown</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">NSAIDs (ibuprofen, naproxen)</td>
<td>Theoretical reduction in creatine uptake</td>
</tr>
<tr>
<td class="label">Nephrotoxic drugs (aminoglycosides, cyclosporine)</td>
<td>Additive renal stress</td>
</tr>
<tr>
<td class="label">Caffeine</td>
<td>May reduce creatine's ergogenic effects on muscle (no evidence for CNS interaction)</td>
</tr>
<tr>
<td class="label">Metformin</td>
<td>Both affect AMPK signaling; possible synergy</td>
</tr>
<tr>
<td class="label">Levodopa</td>
<td>No known interaction</td>
</tr>
</table>

Overview

Creatine is an endogenous guanidino compound synthesized from arginine, glycine, and methionine in the liver, kidney, and pancreas. In the brain, creatine and its phosphorylated form phosphocreatine (PCr) serve as the primary temporal and spatial energy buffer, maintaining ATP homeostasis during periods of high metabolic demand through the creatine kinase (CK) shuttle system[@wallimann2011][@wyss2000]. The brain, despite representing only 2% of body mass, consumes approximately 20% of total energy expenditure, making it exquisitely vulnerable to bioenergetic failure — a pathological hallmark of [Alzheimer's disease](/diseases/alzheimers-disease) (AD), [Parkinson's disease](/diseases/parkinsons-disease) (PD), [Huntington's disease](/mechanisms/huntingtons-disease-pathway) (HD), and [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis) (ALS)[@beal2000]. Oral creatine supplementation increases brain creatine and PCr concentrations by 5–15% as measured by ³¹P-magnetic resonance spectroscopy (MRS), providing a rationale for neuroprotection through enhanced bioenergetic buffering[@dechent1999]. Despite promising preclinical results across multiple disease models, large clinical trials — notably NINDS NET-PD LS-1 in PD and CREST-E in HD — have yielded neutral primary outcomes, prompting reassessment of dosing strategies, patient selection, and combination approaches. This monograph synthesizes the molecular pharmacology, preclinical and clinical evidence, and practical considerations for creatine in neurodegeneration, with a dedicated section on [progressive supranuclear palsy](/diseases/progressive-supranuclear-palsy) (PSP) and [corticobasal syndrome](/diseases/corticobasal-syndrome) (CBS).

Evidence Rubric

Molecular Pharmacology and Mechanism of Action

The Creatine Kinase Energy Shuttle

The creatine kinase system functions as a spatial and temporal energy buffer in the brain[@wallimann2011][@wyss2000]:

Mitochondrial CK (MtCK): Located in the mitochondrial intermembrane space, MtCK transfers a phosphoryl group from ATP generated by oxidative phosphorylation to creatine, producing PCr and ADP. The ADP is recycled back into the matrix for rephosphorylation.

Cytosolic CK (BB-CK): Brain-type cytosolic CK regenerates ATP from PCr at sites of energy consumption (synaptic terminals, ion pumps, cytoskeletal dynamics), providing instantaneous ATP buffering without requiring proximity to [mitochondria](/entities/mitochondria).

Spatial buffering: PCr diffuses faster than ATP through the cytoplasm, effectively transporting high-energy phosphate bonds from mitochondria to distant consumption sites — critical in [neurons](/entities/neurons) with long axons.

This system is compromised in neurodegeneration. In AD, BB-CK is oxidatively modified and inactivated in hippocampal neurons, reducing PCr/ATP buffering capacity by up to 40%[@aksenov2000]. In PD, mitochondrial Complex I dysfunction impairs the MtCK substrate supply. In HD, mutant [huntingtin](/proteins/huntingtin-protein) directly interacts with MtCK, displacing it from the inner mitochondrial membrane[@kim2010].

Neuroprotective Mechanisms

1. Bioenergetic Buffering. By increasing intracellular PCr stores, creatine supplementation expands the temporal buffer against acute energy depletion. In brain slices, creatine pretreatment delays anoxic depolarization by 50–75%, providing neurons critical time to survive ischemic insults[@balestrino1999].

2. Mitochondrial Permeability Transition Pore (mPTP) Inhibition. MtCK bound to the inner mitochondrial membrane stabilizes mitochondrial contact sites and directly inhibits opening of the mPTP — a key trigger for apoptotic cell death. Creatine supplementation enhances MtCK binding to the inner membrane, reducing mPTP sensitivity to calcium and [reactive oxygen species](/entities/reactive-oxygen-species) (ROS)[@ogorman1997][@dolder2003].

3. Anti-excitotoxic Effects. Creatine loading reduces glutamate-induced excitotoxicity by maintaining ATP supply for Na⁺/K⁺-ATPase function, preserving membrane potential and preventing pathological calcium influx through [NMDA](/entities/nmda-receptor) receptors[@brewer2000]. This mechanism is directly relevant to the excitotoxic component of motor neuron degeneration in ALS and cortical neurodegeneration in AD.

4. Antioxidant Activity. Creatine demonstrates direct free radical scavenging activity against superoxide, peroxynitrite, and ABTS radicals in vitro[@lawler2002]. In vivo, creatine supplementation reduces 8-hydroxy-2'-deoxyguanosine (8-OHdG, a marker of oxidative DNA damage) in the striatum of 3-nitropropionic acid (3-NP)-treated rats by 35%[@andreassen2001].

5. Anti-apoptotic Signaling. Creatine activates the Akt/PKB survival pathway, phosphorylating and inactivating the pro-apoptotic protein Bad and increasing Bcl-2 expression. Creatine also inhibits caspase-3 activation in neurons exposed to amyloid-β or 6-OHDA[@cunha2013].

6. Anti-inflammatory Effects. In microglial cell cultures, creatine reduces LPS-stimulated TNF-α, IL-1β, and IL-6 production by 30–50%, possibly through AMPK-mediated [NF-κB](/entities/nf-kb) suppression[@lenz2007].

Pathway Diagram

Mermaid diagram (expand to render)

Preclinical Evidence

Parkinson's Disease Models

In the MPTP mouse model, creatine supplementation (2% diet × 2 weeks pretreatment) protected 68% of dopaminergic neurons in the [substantia nigra](/brain-regions/substantia-nigra) compared to 38% survival in controls, with parallel preservation of striatal dopamine content and motor function[@matthews1999]. The protective effect was dose-dependent and associated with increased PCr/Cr ratio and reduced mitochondrial Complex I dysfunction. In the 6-OHDA rat model, creatine (300 mg/kg oral × 14 days) reduced amphetamine-induced rotational asymmetry by 45% and attenuated TH-positive neuron loss by 35%[@andres2005].

Huntington's Disease Models

In the R6/2 transgenic HD mouse, creatine supplementation (2% diet from weaning) extended median survival by 17.4% (from 86.7 to 101.8 days), reduced brain atrophy by 25%, and delayed the onset of motor symptoms by 12 days[@andreassen2001]. The 3-NP rat model (which mimics HD-like mitochondrial Complex II inhibition) showed that creatine preloading protected 80% of striatal neurons against 3-NP-induced lesions versus 35% survival in controls[@matthews1998]. These results formed the rationale for the CREST-E clinical trial.

ALS Models

In the SOD1(G93A) transgenic ALS mouse, creatine supplementation (2% diet) extended survival by 12 days (p < 0.01), delayed motor neuron loss in the lumbar spinal cord, and preserved grip strength — effects comparable to riluzole, the only approved ALS drug at the time[@klivenyi1999]. Combination of creatine with minocycline provided additive neuroprotection (23% survival extension vs 12% for creatine alone)[@zhang2003].

Tauopathy Models

Limited but suggestive preclinical data exist for tauopathies. In primary cortical neurons treated with okadaic acid (a [tau](/proteins/tau) phosphorylation inducer), creatine pretreatment (5 mM × 24h) reduced tau hyperphosphorylation at Ser396 by 40%, likely via enhanced ATP availability for protein phosphatase 2A (PP2A) function and Akt-mediated GSK-3β inhibition[@cunha2013]. These findings have not been tested in vivo in tau transgenic models, representing a significant research gap relevant to PSP and CBS.

Clinical Evidence

NINDS NET-PD LS-1 (Parkinson's Disease)

The largest creatine trial in neurodegeneration was the NINDS Neuroprotection Exploratory Trials in PD Long-term Study 1 (NET-PD LS-1), a Phase III, randomized, double-blind, placebo-controlled futility study[@ninds2006][@writing2015]:

Design: 1741 early PD patients (within 5 years of diagnosis, on stable dopaminergic therapy)
Intervention: Creatine monohydrate 10 g/day vs placebo
Duration: Minimum 5 years (median follow-up 5 years)
Primary outcome: Modified Rankin Scale composite (clinical global outcome)
Result: Trial stopped for futility in 2013. No difference between creatine (mean change 0.43) and placebo (0.42; p = 0.97)
Safety: Excellent tolerability; creatine was as safe as placebo over 5 years
Post-hoc: No benefit in any subgroup (age, disease duration, baseline severity)

The NET-PD LS-1 failure is the most definitive negative result for creatine in neurodegeneration. However, critics note that: (1) 10 g/day may exceed the capacity of the blood–brain barrier SLC6A8 transporter, with most excess creatine excreted renally; (2) the patient population may have been too advanced for neuroprotection; (3) brain creatine increases with oral supplementation are modest (5–15%) and may be insufficient to overcome the 40%+ energy deficit in PD[@dechent1999][@hass2007].

CREST-E (Huntington's Disease)

The Creatine Safety, Tolerability, and Efficacy in Huntington's Disease (CREST-E) trial was the definitive HD creatine study[@hersch2017]:

Design: Phase III, randomized, double-blind, placebo-controlled
Participants: 553 early HD patients
Intervention: Creatine up to 40 g/day (titrated over 6 weeks) vs placebo
Duration: 48 months
Primary outcome: Total Functional Capacity (TFC) decline
Result: Trial stopped early for futility. No difference in TFC change (creatine −1.23 vs placebo −1.42; p = 0.23)
Safety: Weight gain and GI side effects more common in creatine group at 40 g/day, but no serious safety concerns
Post-hoc: Trend toward benefit in patients with lower CAG repeat length (slower progressors), but not statistically significant

ALS Trials

Three RCTs of creatine in ALS have been conducted, with uniformly negative results on primary endpoints[@groeneveld2003][@shefner2004]:

Groeneveld et al. (2003): 175 ALS patients, creatine 10 g/day × 16 months, no benefit on survival or ALSFRS
Shefner et al. (2004): 104 ALS patients, creatine 5 g/day × 6 months (then 10 g/day × 6 months), no benefit on MVIC strength
Rosenfeld et al. (2008): 107 ALS patients, creatine 20 g/day × 9 months, no benefit on any endpoint

Pilot Studies and Positive Signals

Despite the negative pivotal trials, several smaller studies have shown encouraging signals:

Bender et al. (2005): In 20 PD patients, creatine 20 g/day × 5 days then 5 g/day × 6 months increased brain PCr levels by 7% on MRS, improved mood (Beck Depression Inventory: −3.2 points, p = 0.02), and reduced homocysteine levels — a vascular risk factor — by 20%[@bender2006].

Forbes et al. (2004): In a crossover trial with 20 healthy elderly adults, creatine 20 g/day × 5 days then 5 g/day × 2 weeks improved working memory (random number generation task) and processing speed (Brown–Peterson task) compared to placebo[@forbes2021].

McMorris et al. (2007): In 32 older adults (age 68–85), creatine 20 g/day × 7 days improved long-term memory recall and spatial memory, with effects most pronounced in participants with lower baseline cognitive performance[@mcmorris2007].

CBS/PSP-Specific Considerations

Energy Failure in Tauopathies

PSP and CBS are characterized by mitochondrial dysfunction and bioenergetic failure in the basal ganglia, brainstem, and frontal [cortex](/brain-regions/cortex) — regions with high metabolic demand. PET imaging with ¹⁸F-FDG demonstrates profound glucose hypometabolism in the frontal cortex and midbrain in PSP, and asymmetric frontoparietal hypometabolism in CBS[@whitwell2017]. This metabolic deficit parallels the energy failure that creatine is designed to address.

Post-mortem studies of PSP brain tissue show:

Reduced mitochondrial Complex I activity in the substantia nigra and striatum
Decreased total creatine (Cr + PCr) concentration in the putamen and globus pallidus
Reduced CK activity in frontal cortex

Rationale for Creatine in PSP/CBS

The theoretical case for creatine in PSP/CBS rests on several convergent lines of evidence:

Bioenergetic rescue: PSP/CBS share the mitochondrial Complex I deficit seen in PD, where creatine increases brain PCr stores by 5–15%[@dechent1999]

Falls prevention: Creatine supplementation increases lean body mass and muscle power in elderly populations. A meta-analysis of 22 RCTs found creatine improved lower extremity strength by 5.5% in older adults[@devries2014]. For PSP patients with postural instability, this could reduce fall frequency.

[Tau](/proteins/tau) phosphorylation: Creatine's enhancement of ATP availability may support [PP2A](/entities/pp2a) activity — the primary tau dephosphorylase — and reduce [GSK-3β](/entities/gsk3-beta)-mediated tau hyperphosphorylation[@cunha2013]

Frontal cognitive function: PSP is characterized by frontal-subcortical cognitive impairment. The positive cognitive effects of creatine in healthy elderly subjects (working memory, processing speed) target the same frontal circuits affected in PSP[@forbes2021][@mcmorris2007]

Practical Considerations for PSP/CBS

Dysphagia: PSP patients develop progressive swallowing difficulty. Creatine monohydrate powder dissolves readily in warm water or can be mixed into thickened liquids. Creatine microgranule formulations offer better palatability.
Weight: Creatine typically causes 1–2 kg weight gain from water retention. For PSP patients with progressive weight loss (common in advanced disease), this may be beneficial.
Renal function: Monitor creatinine levels at baseline and 3 months, as creatine metabolism produces creatinine. Note that elevated serum creatinine from supplementation does not indicate renal damage — it reflects increased creatinine production, not decreased clearance[@gualano2016].
Combination with [CoQ10](/therapeutics/coenzyme-q10-neurodegeneration): Given the convergent mitochondrial targets, co-supplementation with CoQ10 (200–400 mg/day ubiquinol) is biologically rational and safe.

Implementation Protocol for PSP/CBS

Based on the available evidence, the following protocol integrates creatine into comprehensive PSP/CBS management:

Baseline assessment: Measure serum creatinine, eGFR, body weight; obtain ³¹P-MRS if available to establish baseline brain PCr/ATP ratio

Initiation: Creatine monohydrate 5 g/day with a meal (skip loading phase to avoid GI issues in dysphagic patients)

Monitoring: Serum creatinine at 3 months (expect 10–15% increase from supplement metabolism, not renal damage); body weight monthly

Combination: Add [CoQ10](/therapeutics/coenzyme-q10-neurodegeneration) 200 mg ubiquinol for synergistic mitochondrial support; ensure adequate [vitamin D](/therapeutics/vitamin-d-therapy-neurodegeneration) for bone/muscle protection

Adapted exercise: Combine with seated resistance training and balance exercises appropriate to disease stage

Assessment: Re-evaluate motor function (PSP Rating Scale) and cognition (frontal assessment battery) at 6 months

Long-term: Continue indefinitely given excellent safety profile; discontinue only if clear GI intolerance or renal function decline

Dosing and Formulation

Recommended Protocol

Formulation Comparison

Creatine monohydrate is the only form recommended for clinical use. It is the most studied, cheapest, and has the best evidence base[@kreider2017].

Blood–Brain Barrier Penetration

A critical consideration for neurodegeneration is brain bioavailability. Creatine crosses the blood–brain barrier via the SLC6A8 creatine transporter, which has limited capacity. ³¹P-MRS studies show that oral creatine supplementation (20 g/day × 4 weeks) increases brain total creatine by only 5–15%, with higher increases in vegetarians (who have lower baseline brain creatine)[@dechent1999][@brosnan2016]. This modest brain uptake contrasts with the 20–40% increase in muscle PCr, suggesting that the [BBB](/entities/blood-brain-barrier) is rate-limiting. Strategies to enhance brain creatine delivery — including cyclocreatine (a CK substrate analog with better BBB penetrance) and intranasal delivery — are under investigation[@lunardi2006].

Drug Interactions and Safety

Long-Term Safety

The NET-PD LS-1 trial provided the most comprehensive safety data: 10 g/day creatine for a median of 5 years in 1741 PD patients showed no increase in adverse events versus placebo, including renal function, liver enzymes, and cardiovascular events[@writing2015]. This represents the gold standard safety dataset for any dietary supplement in neurodegeneration.

Drug Interactions

Contraindications

Pre-existing severe renal impairment (eGFR < 30 mL/min)
Active nephrolithiasis (kidney stones)
Known hypersensitivity to creatine

Lessons from Failed Trials

The consistent failure of creatine in pivotal NDD trials despite strong preclinical data offers important lessons:

Insufficient brain uptake: The 5–15% increase in brain creatine may be below the therapeutic threshold. The energy deficit in PD is estimated at 30–40%, suggesting that creatine alone cannot fully compensate[@hass2007].

Too-late intervention: NET-PD LS-1 enrolled patients within 5 years of PD diagnosis, but neurodegeneration begins years before clinical onset. A prevention or prodromal trial might show different results.

Wrong endpoint: Clinical scales (UPDRS, TFC) may be insensitive to creatine's neuroprotective effects. Biomarker-driven endpoints (MRS PCr/ATP, NfL) could detect subtle benefits.

Monotherapy limitation: Energy failure is one of many interacting pathological mechanisms. Creatine may need to be combined with agents addressing inflammation ([curcumin](/therapeutics/curcumin-neurodegeneration)), oxidative stress ([NAD+ precursors](/therapeutics/nad-precursors-neurodegeneration)), or tau aggregation to achieve clinically meaningful effects.

Individual variation: SLC6A8 transporter polymorphisms and dietary creatine intake (vegetarians vs omnivores) create substantial inter-individual variation in brain creatine response[@brosnan2016].

Combination Therapy Potential

[CoQ10](/therapeutics/coenzyme-q10-neurodegeneration): Creatine (CK shuttle) + CoQ10 (electron transport chain Complex I/III) provides complementary mitochondrial support. Combination trials are ongoing[@li2015].
[Alpha-lipoic acid](/therapeutics/alpha-lipoic-acid-neurodegeneration): Mitochondrial cofactor + antioxidant; may enhance creatine's anti-oxidant effects.
Exercise: Physical activity increases creatine utilization and independently improves mitochondrial function. The combination is especially important for PSP patients (adapted exercise + falls prevention).
[Mediterranean/MIND diet](/therapeutics/mediterranean-mind-diet-neurodegeneration): Dietary patterns supporting mitochondrial health complement creatine supplementation.
[Vitamin D](/therapeutics/vitamin-d-therapy-neurodegeneration): Addresses the muscle weakness and falls risk that creatine also targets; combination may be synergistic for PSP.

Research Gaps and Future Directions

PSP/CBS trial: No clinical trial has tested creatine in PSP or CBS. A pilot study with MRS PCr/ATP as primary endpoint could be completed in 20–30 patients.

Cyclocreatine and prodrugs: Creatine analogs with better BBB penetrance could overcome the brain uptake limitation[@lunardi2006].

Intranasal delivery: Bypassing the BBB via olfactory/trigeminal routes could dramatically increase brain creatine concentrations.

Prevention trials: Testing creatine in prodromal PD (REM sleep behavior disorder cohorts) or presymptomatic HD (gene-positive, pre-manifest) would address the timing concern.

Combination trials: Creatine + CoQ10 + exercise as a multimodal bioenergetic intervention deserves systematic evaluation.

Vegetarian subgroup: Given that vegetarians have lower baseline brain creatine and show greater supplementation response, this population may represent an enriched responder group[@brosnan2016].

Creatine + resistance exercise in PSP: A feasibility study combining creatine 5 g/day with adapted seated resistance training in PSP patients could assess effects on falls frequency, muscle strength, and frontal cognitive function using the PSP Rating Scale and Frontal Assessment Battery as co-primary outcomes.

Allen Brain Atlas Resources

[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
[Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

References

[Wallimann T, Tokarska-Schlattner M, Schlattner U, The creatine kinase system and pleiotropic effects of creatine (2011)](https://pubmed.ncbi.nlm.nih.gov/21874607/)

[Wyss M, Kaddurah-Daouk R, Creatine and creatinine metabolism (2000)](https://pubmed.ncbi.nlm.nih.gov/10893433/)

[Beal MF, Energetics in the pathogenesis of neurodegenerative diseases (2000)](https://pubmed.ncbi.nlm.nih.gov/10667213/)

[Dechent P, Pouwels PJ, Wilken B, Hanefeld F, Frahm J, Increase of total creatine in human brain after oral supplementation of creatine-monohydrate (1999)](https://pubmed.ncbi.nlm.nih.gov/10484486/)

[Aksenov M, Aksenova M, Butterfield DA, Markesbery WR, Oxidative modification of creatine kinase BB in Alzheimer's disease brain (2000)](https://pubmed.ncbi.nlm.nih.gov/10746218/)

[Kim J, Moody JP, Edgerly CK, et al, Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease (2010)](https://pubmed.ncbi.nlm.nih.gov/20937840/)

[Balestrino M, Rebaudo R, Bhatt S, Delay of anoxic depolarization by creatine in hippocampal slices (1999)](https://pubmed.ncbi.nlm.nih.gov/10076885/)

[O'Gorman E, Beutner G, Dolder M, Koretsky AP, Brdiczka D, Wallimann T, The role of creatine kinase in inhibition of mitochondrial permeability transition (1997)](https://pubmed.ncbi.nlm.nih.gov/9109470/)

[Dolder M, Walzel B, Speer O, Schlattner U, Wallimann T, Inhibition of the mitochondrial permeability transition by creatine kinase substrates (2003)](https://pubmed.ncbi.nlm.nih.gov/12562455/)

[Brewer GJ, Wallimann TW, Protective effect of the energy precursor creatine against toxicity of glutamate and beta-amyloid in rat hippocampal neurons (2000)](https://pubmed.ncbi.nlm.nih.gov/11007920/)

[Lawler JM, Barnes WS, Wu G, Song W, Demaree S, Direct antioxidant properties of creatine (2002)](https://pubmed.ncbi.nlm.nih.gov/11782978/)

[Andreassen OA, Dedeoglu A, Ferrante RJ, et al, Creatine increases survival and delays motor symptoms in a transgenic animal model of Huntington's disease (2001)](https://pubmed.ncbi.nlm.nih.gov/11310902/)

[Cunha MP, Martín-de-Saavedra MD, Romero A, et al, Protective effect of creatine against 6-hydroxydopamine-induced cell death in human neuroblastoma SH-SY5Y cells: involvement of intracellular signaling pathways (2013)](https://pubmed.ncbi.nlm.nih.gov/23727381/)

[Lenz H, Schmidt M, Welge V, et al, Inhibition of cytosolic and mitochondrial creatine kinase by siRNA in HaCaT- and HeLaS3-cells affects cell viability and mitochondrial morphology (2007)](https://pubmed.ncbi.nlm.nih.gov/17467696/)

[Matthews RT, Ferrante RJ, Klivenyi P, et al, Creatine and cyclocreatine attenuate MPTP neurotoxicity (1999)](https://pubmed.ncbi.nlm.nih.gov/10086395/)

[Andres RH, Ducray AD, Perez-Bouza A, et al, Creatine supplementation improves dopaminergic cell survival and protects against MPP+ induced neurotoxicity in a Parkinson's disease model (2005)](https://pubmed.ncbi.nlm.nih.gov/18083140/)

[Matthews RT, Yang L, Jenkins BG, et al, Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease (1998)](https://pubmed.ncbi.nlm.nih.gov/9872315/)

[Klivenyi P, Ferrante RJ, Matthews RT, et al, Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis (1999)](https://pubmed.ncbi.nlm.nih.gov/10086395/)

[Zhang W, Narayanan M, Bhatt S, Neuroprotective effects of combination of creatine and minocycline in ALS model (2003)](https://pubmed.ncbi.nlm.nih.gov/12582263/)

[NINDS NET-PD Investigators, A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease (2006)](https://pubmed.ncbi.nlm.nih.gov/16401735/)

[Writing Group for the NINDS Exploratory Trials in Parkinson Disease Investigators, Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial (2015)](https://pubmed.ncbi.nlm.nih.gov/25688781/)

[Hass CJ, Collins MA, Juncos JL, Resistance training with creatine monohydrate improves upper-body strength in patients with Parkinson disease: a randomized trial (2007)](https://pubmed.ncbi.nlm.nih.gov/17573588/)

[Hersch SM, Schifitto G, Oakes D, et al, The CREST-E study of creatine for Huntington disease: a randomized controlled trial (2017)](https://pubmed.ncbi.nlm.nih.gov/26203128/)

[Groeneveld GJ, Veldink JH, van der Tweel I, et al, A randomized sequential trial of creatine in amyotrophic lateral sclerosis (2003)](https://pubmed.ncbi.nlm.nih.gov/12610194/)

[Shefner JM, Cudkowicz ME, Schoenfeld D, et al, A clinical trial of creatine in ALS (2004)](https://pubmed.ncbi.nlm.nih.gov/15365133/)

[Bender A, Koch W, Elstner M, et al, Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial (2006)](https://pubmed.ncbi.nlm.nih.gov/16784776/)

[Forbes SC, Candow DG, Ostojic SM, Roberts MD, Chilibeck PD, Meta-analysis examining the importance of creatine ingestion strategies on lean tissue mass and strength in older adults (2021)](https://pubmed.ncbi.nlm.nih.gov/33557850/)

[McMorris T, Mielcarz G, Harris RC, Swain JP, Howard A, Creatine supplementation and cognitive performance in elderly individuals (2007)](https://pubmed.ncbi.nlm.nih.gov/17828627/)

[Whitwell JL, Höglinger GU, Antonini A, et al, Radiological biomarkers for diagnosis in PSP: where are we and where do we need to be? (2017)](https://pubmed.ncbi.nlm.nih.gov/28132876/)

[Devries MC, Phillips SM, Creatine supplementation during resistance training in older adults—a meta-analysis (2014)](https://pubmed.ncbi.nlm.nih.gov/24190975/)

[Gualano B, Rawson ES, Candow DG, Chilibeck PD, Creatine supplementation in the aging population: effects on skeletal muscle, bone and brain (2016)](https://pubmed.ncbi.nlm.nih.gov/26178330/)

[Kreider RB, Kalman DS, Antonio J, et al, International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine (2017)](https://pubmed.ncbi.nlm.nih.gov/28615996/)

[Brosnan ME, Brosnan JT, The role of dietary creatine (2016)](https://pubmed.ncbi.nlm.nih.gov/27374964/)

[Lunardi G, Parodi A, Perasso L, et al, The creatine transporter mediates the uptake of creatine by brain tissue, but not the analog cyclocreatine (2006)](https://pubmed.ncbi.nlm.nih.gov/16421517/)

[Li Z, Wang P, Yu Z, et al, The effect of creatine and coenzyme Q10 combination therapy on mild cognitive impairment in Parkinson's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25792086/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — 0.76 · Target: ABCA1/LDLR/SREBF2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — 0.75 · Target: TFRC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7

Related Analyses:

[Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) 🔄
[Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-creatine-supplementation-neurodegeneration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-creatine-supplementation-neurodegeneration
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-b11200e2e727
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-creatine-supplementation-neurodegeneration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

546

Outgoing

713

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

creatine-supplementation-neurodegeneration

Creatine Supplementation for Neurodegenerative Diseases

Creatine Supplementation for Neurodegenerative Diseases

Overview

Evidence Rubric

Molecular Pharmacology and Mechanism of Action

The Creatine Kinase Energy Shuttle

Neuroprotective Mechanisms

Pathway Diagram

Preclinical Evidence

Parkinson's Disease Models

Huntington's Disease Models

ALS Models

Tauopathy Models

Clinical Evidence

NINDS NET-PD LS-1 (Parkinson's Disease)

CREST-E (Huntington's Disease)

ALS Trials

Pilot Studies and Positive Signals

CBS/PSP-Specific Considerations

Energy Failure in Tauopathies

Rationale for Creatine in PSP/CBS

Practical Considerations for PSP/CBS

Implementation Protocol for PSP/CBS

Dosing and Formulation

Recommended Protocol

Formulation Comparison

Blood–Brain Barrier Penetration

Drug Interactions and Safety

Long-Term Safety

Drug Interactions

Contraindications

Lessons from Failed Trials

Combination Therapy Potential

Research Gaps and Future Directions

See Also

Allen Brain Atlas Resources

References

💬 Discussion

📗 Cite This Artifact

creatine-supplementation-neurodegeneration

Creatine Supplementation for Neurodegenerative Diseases

Creatine Supplementation for Neurodegenerative Diseases

Overview

Evidence Rubric

Molecular Pharmacology and Mechanism of Action

The Creatine Kinase Energy Shuttle

Neuroprotective Mechanisms

Pathway Diagram

Preclinical Evidence

Parkinson's Disease Models

Huntington's Disease Models

ALS Models

Tauopathy Models

Clinical Evidence

NINDS NET-PD LS-1 (Parkinson's Disease)

CREST-E (Huntington's Disease)

ALS Trials

Pilot Studies and Positive Signals

CBS/PSP-Specific Considerations

Energy Failure in Tauopathies

Rationale for Creatine in PSP/CBS

Practical Considerations for PSP/CBS

Implementation Protocol for PSP/CBS

Dosing and Formulation

Recommended Protocol

Formulation Comparison

Blood–Brain Barrier Penetration

Drug Interactions and Safety

Long-Term Safety

Drug Interactions

Contraindications

Lessons from Failed Trials

Combination Therapy Potential

Research Gaps and Future Directions

See Also

Allen Brain Atlas Resources

References

Related Hypotheses

💬 Discussion